Tuberculosis Surveillance in Hospital Employees: Are We Doing Too Much?

Hypoglycemia-associated In-stent Thrombosis: Are We Doing Too Much?

Diabetes mellitus is one of the most common modifiable risk factors for coronary artery disease, and its prevalence is rising globally. Persistent hyperglycemia has a well-established cardiovascular risk, and its treatment plays an important role in the prevention of future cardiovascular events. While we improved microvascular complications such as retinopathy, nephropathy, and neuropathy by s...

Are We Consuming Too Much

I s humanity’s use of Earth’s resources endangering the economic possibilities open to our descendants? There is wide disagreement on the question. Many people worry about the growth in our use of natural resources over the past century. Some of this increase reflects the higher resource demands from a growing world population. But it also reflects the growth of per capita output and consumptio...

Are we spending too much on HIV?

Are we consuming too much--for what?

HERMAN E. DALY,∗ BRIAN CZECH,† DAVID L. TRAUGER,‡ WILLIAM E. REES,§ MANSI GROVER, TRACY DOBSON,†† AND STEPHEN C. TROMBULAK‡‡ ∗School of Public Affairs, Van Munching Hall, University of Maryland, College Park, MD 20742-1821, U.S.A., email [email protected] †Department of Wildlife and Fisheries Sciences, Virginia Polytechnic Institute and State University, National Capital Region, Alexandria Center, ...

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

We describe the development and approval of biologically targeted agents in the clinic through examples chosen from the experience with inhibitors of the epidermal growth factor (EGF) and VEGF pathways. Despite extensive biological rationale for the use of these classes of molecules, marginal clinical benefits have been observed in broad patient populations, and the agents have entered into gen...